Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program
Translational Therapeutics (United States) · Philadelphia VA Medical Center · +35 more institutions
Abstract
One of the justifiable criticisms of human genetic studies is the underrepresentation of participants from diverse populations. Lack of inclusion must be addressed at-scale to identify causal disease factors and understand the genetic causes of health disparities. We present genome-wide associations for 2068 traits from 635,969 participants in the Department of Veterans Affairs Million Veteran Program, a longitudinal study of diverse United States Veterans. Systematic analysis revealed 13,672 genomic risk loci; 1608 were only significant after including non-European populations. Fine-mapping identified causal variants at 6318 signals across 613 traits. One-third ( n = 2069) were identified in participants from…
Citation impact
- FWCI
- 169.42
- Percentile
- 100%
- References
- 70
Authors
71- AVAnurag VermaCorresponding
Translational Therapeutics (United States), Philadelphia VA Medical Center, University of Pennsylvania
- JEJennifer E. HuffmanCorresponding
Harvard University, VA Boston Healthcare System, Palo Alto Veterans Institute for Research
- AAAlex A RodriguezCorresponding
Argonne National Laboratory
- MCMitchell ConeryCorresponding
Translational Therapeutics (United States)
- MLMolei LiuCorresponding
New York University, Columbia University
Topics & keywords
- Genetic architecture
- Genome-wide association study
- Genetic diversity
- Diversity (politics)
- Scale (ratio)
- Biology
- Evolutionary biology
- Genetics
- Reduced inequalities
Funding
- UDU.S. Department of EnergyAwards: AC05-00OR22725, DE-AC05, 00OR22725
- UDU.S. Department of Veterans AffairsAwards: IK2-CX001780, DE-AC05-00OR22725, UL1TR002548, I01CX001849, BX004189, I01CX001849-01, MVP000, P30 EY025585
- BBattelleAwards: DE-AC05, DE-AC05-00OR22725
- AAstraZeneca
- GGlaxoSmithKline
- OOOffice of Research and DevelopmentAward: MVP000
- APAlnylam Pharmaceuticals
- CCelgene
- UOUniversity of Utah
- ASAmerican Society of Clinical Psychopharmacology
- PParexel
- UUT-BattelleAwards: DE-AC05-, AC05-00OR22725
- NNNovo Nordisk
- APAstellas Pharma
- HLH. Lundbeck A/S
- NINational Institutes of HealthAwards: K08MH122911, UL1TR002548, DK126194, P30AR072577, DE-AC05-00OR22725, AA028259, R01AG065582, P30 EY011373, P30 EY025585, EY011373, EY025585, R01AG067025
- OOOffice of ScienceAwards: DE-AC05-00OR22725, AC05-00OR22725
- CAClinical and Translational Science Collaborative of Cleveland, School of Medicine, Case Western Reserve UniversityAward: UL1TR002548
- NINational Institute of General Medical SciencesAwards: R01GM138597, DE-AC05-00OR22725
- NINational Institute of Diabetes and Digestive and Kidney DiseasesAward: DK126194
- UNU.S. National Library of Medicine
- NCNational Center for Advancing Translational SciencesAward: UL1TR002548
- JPJanssen Pharmaceuticals
- OROak Ridge National LaboratoryAward: AC05-00OR22725